Difficult-to-treat RA: are we any closer to predicting who is at risk? 4 years ago EULAR published its definition of D2T RA. This marked a formal recognition of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic. https://t.co/kQJeUiRNtY https://t.co/xJEVihBMfm

EULAR 2024 – Day 3 Report We are sharing a few of our favorite abstracts and presentations from today, day 3 in Vienna. https://t.co/XgceAQFVQC https://t.co/80jrjv6Awn

PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. https://t.co/l2M19PwhzP https://t.co/f3TGBVszU4

Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. https://t.co/1svlH2GW9W https://t.co/oT1ZOPdR8e

A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. https://t.co/VUfsi3HnAA https://t.co/RA9kuuJSUS

JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. https://t.co/G96x5UMZOX https://t.co/4cOuIbcHVt

Transition from Psoriasis to PsA: Can we Prevent It? Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. https://t.co/MnHG9DgA3H https://t.co/Vht33gWVlC

Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. https://t.co/HKapiAIHSs https://t.co/QrO4pVNOTo

When patients say their joints are swollen, what does it mean? Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows: - some correlation w/ MRI/USS findings - predicts RA development - still worthwhile! #EULAR2024 POS0609 @drdavidliew https://t.co/cRl5ow1emE

ComOA- a cohort study from 3.4 million, 4 countries looked at OA (n=845K) & comorbidities. Tops were LBP (44%), HTN, (34%), allergy (21%), cataract (16%), vertigo (14%), depression (13%), DM (13%). After OA Dx: Fm, RA, PMR OP0230 #EULAR2024 https://t.co/GMVCHSfyt0 https://t.co/KFlacpHfAX

#POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the 1st 3mths only #EULAR2024 @Yuz6Yusof https://t.co/tOOvvVynKA